FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1974866721> ?p ?o ?g. }

• W1974866721 abstract "To examine potential differences in efficacy and safety of treatment with olanzapine in patients with schizophrenia of white and black descent.A post-hoc, pooled analysis of 6 randomized, double-blind trials in the treatment of schizophrenia, schizophreniform disorder, or schizoaffective disorder compared white (N = 605) and black (N = 375) patients treated with olanzapine (5 to 20 mg/day) for 24 to 28 weeks. Efficacy measurements included the Positive and Negative Syndrome Scale (PANSS) total score; and positive, negative, and general psychopathology scores; and the Clinical Global Impression of Severity (CGI-S) scores at 6 months. Safety measures included differences in the frequencies of adverse events along with measures of extrapyramidal symptoms, weight, glucose, and lipid changes over time.51% of black patients and 45% of white patients experienced early study discontinuation (P = .133). Of those who discontinued, significantly more white patients experienced psychiatric worsening (P = .002) while significantly more black patients discontinued for reasons other than efficacy or tolerability (P = .014). Discontinuation for intolerability was not different between groups (P = .320). For the estimated change in PANSS total score over 6 months, there was no significant difference in efficacy between white and black patients (P = .928), nor on the estimated PANSS positive (P = .435), negative (P = .756) or general psychopathology (P = .165) scores. Overall, there was no significant difference in the change in CGI-S score between groups from baseline to endpoint (P = .979). Weight change was not significantly different in white and black patients over 6 months (P = .127). However, mean weight change was significantly greater in black versus white patients at Weeks 12 and 20 only (P = .028 and P = .026, respectively). Additionally, a significantly greater percentage of black patients experienced clinically significant weight gain (≥ 7%) at anytime compared to white patients (36.1% vs. 30.4%, P = .021). Changes across metabolic parameters (combined fasting and random lipids and glucose) were also not significantly different between groups, with the exception of a greater categorical change in total cholesterol from borderline to high among white subjects and a categorical change from normal to low in high density lipoprotein (HDL) cholesterol among white males.The findings did not demonstrate overall substantive differences in efficacy or safety between white and black patients diagnosed with schizophrenia or related disorders treated with olanzapine. However, a significantly greater percentage of black patients (36.1%) experienced clinically significant weight gain compared to white patients (30.4%)." @default.
• W1974866721 created "2016-06-24" @default.
• W1974866721 creator A5015085334 @default.
• W1974866721 creator A5018010521 @default.
• W1974866721 creator A5027670144 @default.
• W1974866721 creator A5046693741 @default.
• W1974866721 creator A5049121567 @default.
• W1974866721 creator A5051627719 @default.
• W1974866721 creator A5060395372 @default.
• W1974866721 creator A5072374259 @default.
• W1974866721 date "2010-11-03" @default.
• W1974866721 modified "2023-10-01" @default.
• W1974866721 title "Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder" @default.
• W1974866721 cites W196008488 @default.
• W1974866721 cites W1966300584 @default.
• W1974866721 cites W1983133139 @default.
• W1974866721 cites W1990619105 @default.
• W1974866721 cites W2001604573 @default.
• W1974866721 cites W2014655066 @default.
• W1974866721 cites W2016947285 @default.
• W1974866721 cites W2017667457 @default.
• W1974866721 cites W2019473091 @default.
• W1974866721 cites W2022773983 @default.
• W1974866721 cites W2049994834 @default.
• W1974866721 cites W2051732292 @default.
• W1974866721 cites W2052198771 @default.
• W1974866721 cites W2068439158 @default.
• W1974866721 cites W2076484723 @default.
• W1974866721 cites W2079367967 @default.
• W1974866721 cites W2084624509 @default.
• W1974866721 cites W2092264845 @default.
• W1974866721 cites W2094539285 @default.
• W1974866721 cites W2095927831 @default.
• W1974866721 cites W2100219462 @default.
• W1974866721 cites W2112310612 @default.
• W1974866721 cites W2115050488 @default.
• W1974866721 cites W2117058794 @default.
• W1974866721 cites W2122206301 @default.
• W1974866721 cites W2125344848 @default.
• W1974866721 cites W2139275756 @default.
• W1974866721 cites W2142301120 @default.
• W1974866721 cites W2143241112 @default.
• W1974866721 cites W2143578692 @default.
• W1974866721 cites W2146721709 @default.
• W1974866721 cites W2157851293 @default.
• W1974866721 cites W2159155203 @default.
• W1974866721 cites W2161394544 @default.
• W1974866721 cites W2166701818 @default.
• W1974866721 cites W2170750192 @default.
• W1974866721 cites W4213000396 @default.
• W1974866721 cites W4238251256 @default.
• W1974866721 cites W4252201458 @default.
• W1974866721 doi "https://doi.org/10.1186/1471-244x-10-89" @default.
• W1974866721 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3020682" @default.
• W1974866721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21047395" @default.
• W1974866721 hasPublicationYear "2010" @default.
• W1974866721 type Work @default.
• W1974866721 sameAs 1974866721 @default.
• W1974866721 citedByCount "20" @default.
• W1974866721 countsByYear W19748667212012 @default.
• W1974866721 countsByYear W19748667212013 @default.
• W1974866721 countsByYear W19748667212014 @default.
• W1974866721 countsByYear W19748667212015 @default.
• W1974866721 countsByYear W19748667212016 @default.
• W1974866721 countsByYear W19748667212017 @default.
• W1974866721 countsByYear W19748667212019 @default.
• W1974866721 countsByYear W19748667212020 @default.
• W1974866721 countsByYear W19748667212021 @default.
• W1974866721 countsByYear W19748667212023 @default.
• W1974866721 crossrefType "journal-article" @default.
• W1974866721 hasAuthorship W1974866721A5015085334 @default.
• W1974866721 hasAuthorship W1974866721A5018010521 @default.
• W1974866721 hasAuthorship W1974866721A5027670144 @default.
• W1974866721 hasAuthorship W1974866721A5046693741 @default.
• W1974866721 hasAuthorship W1974866721A5049121567 @default.
• W1974866721 hasAuthorship W1974866721A5051627719 @default.
• W1974866721 hasAuthorship W1974866721A5060395372 @default.
• W1974866721 hasAuthorship W1974866721A5072374259 @default.
• W1974866721 hasBestOaLocation W19748667211 @default.
• W1974866721 hasConcept C118552586 @default.
• W1974866721 hasConcept C123273963 @default.
• W1974866721 hasConcept C126322002 @default.
• W1974866721 hasConcept C142724271 @default.
• W1974866721 hasConcept C15744967 @default.
• W1974866721 hasConcept C197934379 @default.
• W1974866721 hasConcept C204787440 @default.
• W1974866721 hasConcept C27081682 @default.
• W1974866721 hasConcept C2776000289 @default.
• W1974866721 hasConcept C2776412080 @default.
• W1974866721 hasConcept C2776619155 @default.
• W1974866721 hasConcept C2777393122 @default.
• W1974866721 hasConcept C2778375690 @default.
• W1974866721 hasConcept C2778715236 @default.
• W1974866721 hasConcept C2779437044 @default.
• W1974866721 hasConcept C2779727114 @default.
• W1974866721 hasConcept C2780135775 @default.
• W1974866721 hasConcept C2780325297 @default.
• W1974866721 hasConcept C2780494398 @default.
• W1974866721 hasConcept C2780616385 @default.
• W1974866721 hasConcept C71924100 @default.

• next